Investigating the role of immunoglobulin replacement therapy in patients receiving CAR-T cell therapy for B cell malignancies
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy
This study is looking at how immunoglobulin replacement therapy might help patients who have received CAR-T cell therapy for B cell cancers by seeing if it can lower their chances of getting infections compared to a placebo, while also checking how it affects their CAR-T cells and healthcare needs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10915043 on NIH RePORTER |
What this research studies
This research focuses on understanding how immunoglobulin replacement therapy (IGRT) affects patients who have undergone CD19-targeted CAR-T cell therapy for B cell malignancies. The study aims to determine whether IGRT can reduce infection rates in these patients compared to a placebo, while also examining its impact on CAR-T cell function and overall healthcare resource utilization. By conducting a randomized, controlled trial, the research seeks to provide critical insights into the benefits and risks associated with IGRT in this specific patient population.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older who have received CD19-targeted CAR-T cell therapy for B cell malignancies and are experiencing hypogammaglobulinemia.
Not a fit: Patients who have not undergone CAR-T cell therapy or those without hypogammaglobulinemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved infection prevention strategies for patients undergoing CAR-T cell therapy, enhancing their overall treatment outcomes.
How similar studies have performed: This research is novel as it represents the first randomized, controlled trial specifically examining the use of immunoglobulin replacement therapy in CAR-T cell therapy recipients.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Hill, Joshua Aiden — Fred Hutchinson Cancer Center
- Study coordinator: Hill, Joshua Aiden
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.